Why this diabetes shot might save your heart
Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Doctors give two kinds of shots to people with type 2 diabetes when pills aren't enough: one is GLP-1RA, the other is basal insulin. This study looked at which one is safer for the heart.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 566 / 72
Evidence Score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Doctors give two kinds of shots to people with type 2 diabetes when pills aren't enough: one is GLP-1RA, the other is basal insulin. This study looked at which one is safer for the heart.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 566 / 72
Evidence Score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Publication
Authors
Longato E, Di Camillo B, Sparacino G, Tramontan L, Avogaro A, Fadini GP
Related Content
Claims (5)
GLP-1 receptor agonists confer cardiovascular and metabolic benefits in type 2 diabetes and prediabetes through direct receptor-mediated mechanisms that are independent of weight loss and distinct from endogenous incretin enhancement.
Among adults with type 2 diabetes who start injectable treatment, those who begin a GLP-1 receptor agonist have a 41% lower risk of dying from any cause and a 41% lower risk of having a stroke over two years compared to those who start basal insulin, based on observed data adjusted for other health factors.
Among adults with type 2 diabetes starting injectable treatment, those using GLP-1 receptor agonists had a lower risk of heart attack, stroke, or death over two years compared to those using basal insulin, based on statistical analysis of patient data.
In adults with type 2 diabetes who start injectable diabetes medication, those using GLP-1 receptor agonists have a lower risk of having a heart attack or being hospitalized for heart failure compared to those using basal insulin, over a period of about two years, regardless of whether they had prior heart disease.
For adults with type 2 diabetes starting injectable treatment, GLP-1 receptor agonists are linked to a 44% lower risk of severe low blood sugar episodes compared to basal insulin over two years.